Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408697 | 1.00 | GHSR (0.49) | GHSROPRD1F2CYP51A1DPP4 | |
| SCHEMBL867796 | 0.87 | GHSR (0.56) | GHSROPRD1F2CYP51A1 | |
| SCHEMBL867797 | 0.87 | GHSR (0.56) | GHSROPRD1F2CYP51A1 | |
| SCHEMBL6319127 | 0.85 | GHSR (0.53) | GHSR | |
| SCHEMBL6325995 | 0.84 | GHSR (0.54) | GHSR | |
| SCHEMBL14106527 | 0.83 | GHSR (0.55) | GHSROPRD1F2 | |
| SCHEMBL867815 | 0.82 | GHSR (0.54) | GHSROPRD1F2 | |
| SCHEMBL867816 | 0.82 | GHSR (0.54) | GHSROPRD1F2 | |
| SCHEMBL6318514 | 0.82 | GHSR (0.52) | GHSR | |
| SCHEMBL1401210 | 0.80 | GHSR (0.56) | GHSROPRD1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | disclosed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | GHSR, GHRHR, MC2R | GHSR 1/4885OPRD1 681/4885F2 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.